Podcasts about Dato

Enrique Quintana, Dir. general editorial de El Financiero

Hay gestos cruzados y tensiones abiertas dentro del progre-peronismo fueguino. Algunos empujan unidad, otros confirman distancias.Dato preocupante: en Radio Nacional Ushuaia quitaron redes, congelaron salarios y ahora censuran temas políticos. La radio pública pierde voz en un contexto delicado.Se viene un año duro en educación. SUTEF no está conforme con la oferta salarial y le marcó a Melella el tema RIGI.Todo esto en la Pastilla de Gamera!

Podcast de Inversión Inmobiliaria

El 40 por ciento de las mujeres con discapacidad aseguran que han sufrido algún tipo de violencia de género. Así se desprende del informe “Ojo al dato. Visibilidad de una realidad oculta a través del dato: mujer, discapacidad y violencia”, elaborado por Fundación ONCE e Inserta Empleo.Escuchar audio

Conozca el dato de veeduría que entrega la Corporación Cívica de Caldas sobre bulevar San Jorge. Regional by LA PATRIA

In this episode of The Safi Bros Podcast - Singer, Actor, Motivational Consultant, Host, Chef and Father, Dato' Fazley Yaakob shares the trials that shaped his legacy beyond the spotlight.A huge thanks to Fazley for such an amazing discussion.For the video podcast, find us on:

Il Messaggio di Oggi: “POICHÈ A CHIUNQUE HA SARÀ DATO” • Matteo 25: 29-30 • Matteo 22: 13 • Ebrei 11: 6 • Luca 16: 10 • 1 Samuele 26 :23 • 1 Samuele 26: 25 • 1 Samuele 24: 21 • Matteo 25: 21 • 1 Samuele 24 :18 • 1 Samuele 15: 28 • 1 Cronache 29 :28 • 1 Samuele 24: 5-6 • Luca 16: 10 • Malachia 3 :10 • Matteo 25: 26 • Matteo 25: 25 • Matteo 25: 14 • 1 Corinzi 4: 1 • Luca 6: 38 • Genesi 26: 12 --Guarda Canale 245 | Tivùsat 454 | Sky 854Scopri di più su www.paroledivita.org/linkinbio

DATO SOBRE DATO con Daniel Santoro y José Luis Brea 20-02-2026 Entrevistas a: Jorge Triaca @JorgeTriaca (Exministro de Trabajo de la Nación) Juan Luis Bour (Director y Economista Jefe de FIEL @Fundacion_FIEL )

Jorge Triaca @JorgeTriaca (Exministro de Trabajo de la Nación) Dato Sobre Dato @DatosobreDato

Juan Luis Bour (Director y Economista Jefe de FIEL @Fundacion_FIEL ) Dato Sobre Dato @DatosobreDato

Cada semana en Onda Cero junto a Agustín Bravo, Sergio Alberto Gama y Beatriz Martínez analizamos la seguridad vial. Cinturón de seguridad en el tren vs el autobús y el coche ¿Por qué es obligatorio y vital en un coche, opcional o ignorado en un autobús, y prácticamente inexistente en un tren? Característica Coche (Turismo) Autobús (Interurbano) Tren (Renfe/Alta Velocidad) Obligatoriedad 100% obligatoria para todos los ocupantes. Obligatorio si el vehículo los equipa (desde 2007). No existe obligación ni instalación. Cumplimiento Real Alto, pero el 25% de fallecidos en 2025 no lo usaba. Muy bajo. Rara vez se usa en trayectos largos. N/A Riesgo principal Choque frontal, lateral y salida de vía. Volcamiento (vuelco) y colisión. Descarrilamiento o colisión masiva. Efectividad Máxima: evita el impacto contra el interior. Alta: evita la eyección en caso de vuelco. Baja: el diseño del coche es la protección. 1. El Coche: El "Salvavidas" Indispensable En un coche, la deceleración en un choque es casi instantánea. Sin cinturón, el cuerpo sigue moviéndose a la velocidad que llevaba el vehículo hasta que golpea el volante, el parabrisas o sale despedido. • Física: El espacio de supervivencia es pequeño. El cinturón es la pieza clave que permite que el Airbag funcione correctamente. • Dato 2025: Como vimos en el balance que compartiste, sigue siendo inaceptable que 1 de cada 4 fallecidos en turismo aún no lo utilizara. 2. El Autobús: Protección contra el Vuelco En los autobuses, el peligro no es tanto el choque frontal (debido a su gran masa), sino el vuelco. • Por qué no se usa tanto: Existe una falsa sensación de seguridad por el tamaño del vehículo. Además, la vigilancia a bordo es difícil. • La función real: En un vuelco, el cinturón evita que los pasajeros "caigan" unos sobre otros o salgan despedidos por las ventanillas, que es la principal causa de muerte en estos siniestros. • Normativa: En España, desde 2007, todos los autobuses nuevos deben matricularse con cinturones, pero la responsabilidad de abrochárselo es del pasajero. 3. El Tren: ¿Por qué no hay cinturones? Es la pregunta del millón. La ausencia de cinturones en trenes de alta velocidad o cercanías no es un descuido, sino una decisión de ingeniería basada en la seguridad pasiva. • La masa y la deceleración: Un tren pesa cientos de toneladas. En una colisión, la deceleración es mucho más lenta y progresiva que en un coche. El tren no se detiene de 100 a 0 km/h en un metro. • Compartimentación: Los asientos están diseñados para absorber energía. En caso de impacto, el pasajero es "atrapado" por el asiento delantero, que es deformable. • Riesgo de atrapamiento: En siniestros ferroviarios (como incendios o caídas al agua), el cinturón podría ser contraproducente, impidiendo una evacuación rápida. Los estudios indican que el cinturón en trenes no reduciría significativamente las lesiones en la mayoría de escenarios de accidentes. Este argumento ha sido respaldado por diferentes estudios e informes. Uno de ellos fue realizado por el organismo británico Rail Safety & Standards Board que en 2007 concluyó que “los cinturones de seguridad en trenes aumentarían el riesgo de lesiones en caso de colisión”. • La investigación identificó que los cinturones de dos puntos provocaban una rotación violenta del cuerpo alrededor de la cintura, aumentando el riesgo de lesiones graves, mientras que los de tres puntos eran incompatibles con los asientos antichoque utilizados en trenes. • El informe también analizó accidentes reales y determinó que, aunque el uso de cinturones podría haber evitado algunas expulsiones del vagón, el balance global sería negativo, ya que muchos pasajeros que salen despedidos del tren “evitan ser aplastados”. • “En el tren no hay aceleraciones y frenados como lo hay en el avión por lo que el riesgo de desplazamiento de personas y objetos es prácticamente cero” Vehículos que no tienen que llevar la Baliza V16 • Motocicletas y ciclomotores (no están obligados a llevarla como dotación). • Bicicletas. • Vehículos con matrícula extranjera que circulen por España (no se les exige la V-16 española). • Vehículos especiales (maquinaria agrícola o de obras). Hasta aquí el programa de hoy del podcast de seguridad vial y educación vial. ¿Quieres escuchar episodios anteriores sobre seguridad en moto? • P138 100 tramos más peligrosos para motoristas https://go.ivoox.com/rf/72292314 • P154 Hugo de 14 años muere en el campeonato Europeo de motociclismo. https://go.ivoox.com/rf/73574655 • P176 Motos sin ITV https://go.ivoox.com/rf/75543112 • P262 Seguridad Vial en moto No me llames paquete https://go.ivoox.com/rf/93733543 • P289 Caídas en quad o moto y la importancia de la equipación adecuada. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101146657 • P300 Seguridad vial en moto en el Dakar https://go.ivoox.com/rf/101515123 • P327 Seguridad vial en moto, formación conducción, compra de equitación y exigir la retirada de guardarraíles asesinos https://go.ivoox.com/rf/105221622 • P376 seguridad vial en moto, episodio 5 del verano de seguridad en Onda Cero https://go.ivoox.com/rf/114152759 • P470 La seguridad vial en moto a debate https://go.ivoox.com/rf/126752010 • P566 chaleco airbag moto para la atgc https://go.ivoox.com/rf/135729959 • P557 4000 motos en la manifestación motera por la seguridad vial https://go.ivoox.com/rf/134812092 • P601 charla de seguridad vial en la concentración motorista La Leyenda en Cantalejo https://go.ivoox.com/rf/137929200 • P610 motoristas maltratados por Juan Carlos toribio en la concentración La Leyenda https://go.ivoox.com/rf/139115892 • P656 que sucede con la seguridad de los motoristas https://go.ivoox.com/rf/149781060 ¿Quieres escuchar episodios anteriores sobre seguridad en Euro NCAP? • P22 Seguridad infantil en Euro NCAP 2020 https://go.ivoox.com/rf/60410726 • P31 La seguridad infantil de los 7 coches ensayados en Euro NCAP 2020 https://go.ivoox.com/rf/63999896 • P119 En AutoFM hablamos del origen de lo que hoy es Euro NCAP https://go.ivoox.com/rf/70766776 • P192 Hyundai Ioniq 5 en Euro NCAP https://go.ivoox.com/rf/77624794 • P200 El coche más seguro para niños según Euro NCAP https://go.ivoox.com/rf/79810679 • P278 ¿Qué es EuroNCAP? https://go.ivoox.com/rf/97118681 • P320 Seguridad EuroNCAP en el Lexus RX https://go.ivoox.com/rf/104093361 • P325 Cupra en Euro NCAP seguridad made in Spain https://go.ivoox.com/rf/104841125 • P353 Euro NCAP y la seguridad de nuestros vehículos https://go.ivoox.com/rf/111970962 • P413 Etiquetas de seguridad en EuroNCAP https://go.ivoox.com/rf/121984964 • P426 BMW Serie 5 en EuroNCAP https://go.ivoox.com/rf/121989858 • P525 el coche más seguro en euro ncap 2023-24 https://go.ivoox.com/rf/132581951 • P617 euro ncap deepal s07 https://go.ivoox.com/rf/143237685 • P619 Xpeng pasa por Euro NCAP https://go.ivoox.com/rf/143237909 • P621 NIO EL6 en EuroNCAP https://go.ivoox.com/rf/143595669 • P655 Euro NCAP Jaecoo 7 https://go.ivoox.com/rf/149781056 ¿Quieres escuchar episodios anteriores sobre patinetes eléctricos (VMP) y su influencia en la educación vial y seguridad vial? • VMP o los patinetes eléctricos (13-11-2020) https://go.ivoox.com/rf/58970634 • P29 200€ de multa a los patinetes que circulen por la acera (19-1-2021) https://go.ivoox.com/rf/63999858 • P39 El 80% de los accidentados en patinete eléctrico iban sin casco. https://go.ivoox.com/rf/64652023 • P88. En la sección de RiveKids dentro de AutoFM hablamos de atropellos de niños con patinete eléctrico VMP https://go.ivoox.com/rf/68488690 • P134 Tráfico dice que se va a poner duro con patinetes y bicicletas https://go.ivoox.com/rf/71998645 • P205 certificado para VMP y manual de características del patinete eléctrico https://go.ivoox.com/rf/81250012 • P222 Normativa del patinete eléctrico en Onda Cero https://go.ivoox.com/rf/86695954 • P228 El patinete eléctrico no es un juguete en Auto FM https://go.ivoox.com/rf/87765635 • P329 lista de patinetes eléctricos certificados por la DGT https://go.ivoox.com/rf/105222377 • P449 Se prohíbe el patinete eléctrico en el metro de Bilbao https://go.ivoox.com/rf/124482727 ¿Quieres escuchar episodios anteriores sobre cómo la DGT afronta la educación vial y seguridad vial? • P47 La DGT recauda más de un millón de euros al día en multas https://go.ivoox.com/rf/65042824 • P68 2.880 conductores fueron denunciados dos o más veces en un mismo año por no llevar el cinturón de seguridad. https://go.ivoox.com/rf/66793732 • P72 La otra cara del rescate en carretera. DGT https://go.ivoox.com/rf/67030950 • P78 ¿Por qué nos denuncia la DGT en España? https://go.ivoox.com/rf/67470851 • P85 los tribunales anulan la mitad de las multas que pone la DGT. https://go.ivoox.com/rf/68027004 • P189 Cómo adelantar con seguridad https://go.ivoox.com/rf/76818386 • 6 puntos por usar el móvil al volante y más cambios de la DGT. https://go.ivoox.com/rf/60394281 • P383 ¿Hay que abrochar el cinturón de seguridad incluso sin ocupantes en las plazas traseras? https://go.ivoox.com/rf/115775880 • P444 Ocurrencias de la DGT en 2024 https://go.ivoox.com/rf/124103189 • P559 estrategia de país en la seguridad vial https://go.ivoox.com/rf/134812303 • P447 Propuestas de la DGT para bajar fallecidos en carretera https://go.ivoox.com/rf/124482117 • P456 La DGT incumple la promesa de retirar la Ley de tráfico si aumentaban los fallecidos https://go.ivoox.com/rf/124862871 • P494 La DGT frena los cambios del carnet de conducir https://go.ivoox.com/rf/130588417 • P538 En un accidente no se multiplica el peso como dice la DGT https://go.ivoox.com/rf/133370042 • P559 estrategia de país en la seguridad vial https://go.ivoox.com/rf/134812303 • P564 la seguridad en los adelantamientos https://go.ivoox.com/rf/135729856 • P633 La DGT controla a los conductores profesionales https://go.ivoox.com/rf/144450395 • P569 la DGT hace campanas de buenismo con los patinetes https://go.ivoox.com/rf/135730039 ¿Quieres escuchar episodios anteriores del podcast de educación vial y seguridad vial? • P6 Coronavirus y Seguridad Vial https://go.ivoox.com/rf/49513283 • P169 Seguridad vial en Onda Cero https://go.ivoox.com/rf/74292123 • P125 ¿Isofix en un SsangYong Rodius? Y mucha más seguridad vial https://go.ivoox.com/rf/71289331 • P196 Seguridad vial para bebés prematuros y CIPSEVI https://go.ivoox.com/rf/78652365 • P168 Sin ruedas no hay seguridad vial https://go.ivoox.com/rf/74292023 • P182 La educación vial en El Enfoque, Onda Madrid https://go.ivoox.com/rf/76018355 • P7 Mascarillas y guantes son al coronavirus lo que el cinturón de seguridad y los SRI a la violencia vial https://go.ivoox.com/rf/50038459 • P197 Estudio sobre la inseguridad vial en el contenido de las series en Capital Radio https://go.ivoox.com/rf/78897119 • P565 la mayoría de gente no usa el cinturón de seguridad https://go.ivoox.com/rf/135729932 • P561 4 de cada 10 conductores dan positivo en drogas https://go.ivoox.com/rf/134812530 • P541 La DGT no sabe dónde hay más de 650 millones de euros https://go.ivoox.com/rf/133580231 ¿Quieres escuchar episodios anteriores del podcast de seguridad vial en el Dakar? • P290 Lluvia torrencial, helicópteros que no pueden volar y buggies en medio de riadas. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101146767 • P291. Señalización de accidentes en la carrera más dura del mundo. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101146815 • P295 Exceso de velocidad, radar, sanción y distancia de frenado. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101147162 • P297 Muere atropellado por conseguir la mejor foto. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101514720 • P302 El Dakar 2023 da una lección de seguridad vial. La velocidad no mata, matan otras cosas. Seguridad vial Dakar https://go.ivoox.com/rf/101515334 • P301 Seguridad Vial con Manolo Plaza en el Dakar y en la vida. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101515325 • P300 La seguridad vial en moto en el Dakar y en las carreteras españolas. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101515123 • P294 Cansancio y fatiga extrema en competición. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101147100 • P296 ¿Es más seguro un chasis tubular? Biomecánica del impacto y aceleraciones en la seguridad vial Dakar 2023 https://go.ivoox.com/rf/101514635 • P288 Arco antivuelco o jaula de seguridad. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/100776113 • P293 Hans. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101146904 • P292. Pos seguridad después de un vuelco o un accidente ¿qué hacer?. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/101146866 • P287 Arnés vs cinturón de seguridad. Seguridad vial Dakar 2023 https://go.ivoox.com/rf/100775999 • P299 Conducir sin luna en la seguridad vial Dakar 2023 https://go.ivoox.com/rf/101515049 • P298 Fallece atropellado un aficionado que estaba viendo el Dakar 2023. Seguridad vial dentro y fuera de la competición https://go.ivoox.com/rf/101514818 • P430 Prologo Dakar 2024, seguridad vial https://go.ivoox.com/rf/122182887 • P438 Etapa 10 Dakar 2024 competición vs vida real en la señalización https://go.ivoox.com/rf/123338733 • P435 Etapa 5 Dakar 2024, la fatiga https://go.ivoox.com/rf/122440640 • P440 Etapa de descanso Dakar 2024 los twit de la DGT https://go.ivoox.com/rf/123339096 • P439 Etapa 11 Dakar 2024 adelantamientos extremos https://go.ivoox.com/rf/123338820 • P436 Atropello de un espectador en el Dakar 2024 https://go.ivoox.com/rf/122440725 • P434 Etapa 4 seguridad jurídica y excesos de velocidad en el Dakar 2024 https://go.ivoox.com/rf/122440464 • P431 Etapa 1 Dakar 2024, espectador atropellado https://go.ivoox.com/rf/122229047 • P432 Etapa 2 Dakar 2024, jaula de seguridad y Carles Falcón https://go.ivoox.com/rf/122229139 • P433 Etapa 3 Dakar 2024, los 3 impactos de un accidente https://go.ivoox.com/rf/122440325 “El verdadero viaje es el que termina como comenzó, con felicidad e inocencia” Feliz viaje hasta el próximo programa. _______________________________________

Episod 189 Keluar Sekejap membincangkan kontroversi terbaharu melibatkan Ketua Pesuruhjaya SPRM, Tan Sri Azam Baki, susulan dakwaan pegangan saham bernilai besar dalam beberapa syarikat tersenarai serta tuduhan kewujudan ‘Corporate Mafia' dalam landskap korporat negara.Episod ini turut menyentuh ketegangan yang semakin terbuka dan memucak antara Perdana Menteri, Dato' Seri Anwar Ibrahim dan Rafizi Ramli.Dalam masa yang sama, keputusan Bersatu memecat Timbalan Presidennya merangkap Ketua Pembangkang, Dato' Seri Hamzah Zainudin, dianalisis dari sudut perebutan kuasa dan kesannya terhadap landskap politik menjelang PRU16.Keluar Sekejap juga membahaskan tindakan PETRONAS memfailkan rujukan ke Mahkamah Persekutuan bagi mendapatkan kepastian perundangan berhubung pertindihan bidang kuasa.Ingin jenama anda dikenali oleh ribuan pendengar?Taja episod Keluar Sekejap 2026!Hubungi +6011-1919 1783 atau emel commercial@ksmedia.my

6 de cada 10 productos que compramos en el supermercado son marcas del propio establecimiento. ¿Cuáles son las causas de la expansión de estos productos en España y cómo se hacen más atractivos?

Niente più asterischi nella classifica di Serie A, ieri si è giocato infatti ilrecupero tra Milan e Como rinviato per via delle Olimpiadi. Gara giàdifficile che si è ulteriormente complicata dopo l'errore di Maignan allamezz'ora del primo tempo che ha portato al vantaggio degli ospiti firmatoNico Paz; come spesso è accaduto in campionato però, i rossoneri hannosaputo reagire evitando la sconfitta.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/radio-rossonera--2355694/support.

Podcast de Inversión Inmobiliaria

Cada clic que hacemos en la web genera múltiples eventos de seguimiento. En este episodio analizamos qué son, por qué existen y cómo forman parte del ecosistema invisible que acompaña a nuestra vida digital cotidiana.

La computación cuántica amenaza la seguridad del blockchain y la escasez energética pone en riesgo el avance tecnológico, advierte López Zafra. El economista Juan Manuel López Zafra afirma que el dato se ha convertido en el activo central de la economía contemporánea, al señalar que su valor proviene del proceso que lo convierte en información y conocimiento. Durante la entrevista, el autor de Alquimia. Cómo los datos se están transformando en oro (Deusto) advirtió sobre el impacto que la computación cuántica tendrá en los sistemas de cifrado actuales, afirmando que "hará franqueable la blockchain". Aunque el eje de la conversación estuvo en los riesgos cuánticos y energéticos, López Zafra contextualizó estas cuestiones dentro del ciclo económico del dato. Definió el dato como una materia prima que solo adquiere valor mediante procesos de interpretación o tratamiento algorítmico. "Un dato sin más es ruido", afirmó. Explicó cómo empresas digitales y tradicionales dependen de esa transformación para ofrecer servicios, anticipar demanda y tomar decisiones operativas. Desde plataformas de movilidad hasta compañías energéticas o infraestructuras hidráulicas, la predicción se ha convertido en un componente esencial: "Una compañía aérea no se entiende históricamente sin la predicción".

Women's football doesn't grow on its own. In this #WomenInSports episode sama-sama kita dengarkan pendapat Dato' Suraya Yaacob about building the ecosystem, leagues, pathways, planning, and support for female athletes. She explains how small structural changes can slowly shape a stronger future for the game in #jomsembang

Martín R. Caranta @mrcaranta (Socio del estudio Lisicki, Litvin y Abelovich @lisickilitvin Consultor Tributario) Dato Sobre Dato @DatosobreDato

Questo episodio è dedicato a come riconoscere la modalità minore.Ascoltiamo subito Bella ciao. E' l'esempio migliore in assoluto della modalità minore perché è una canzone famosissima, conosciuta internazionalmente, ed essendo anche cantata è più facile da ricordare. La conosce anche chi non la ascolta attivamente, cioè anche chi non sceglie di ascoltarla, chi non ha studi musicali, ed è un tema transgenerazionale, che conoscono tutti a prescindere dall'età che hanno.  E' un canto chiaramente in minore: non espande, non addolcisce, guarda in faccia alla realtà nella sua crudità e proprio per questo non consola, non è depressivo né lamentoso. E' seria. E' una dichiarazione di ciò che la realtà è.   Giusto una curiosità di tipo culturale:  Bella ciao deriva da un canto popolare di lavoro delle mondine nelle risaie italiane, con testi sulla fatica e lo sfruttamento, e solo dopo la Seconda Guerra mondiale è diventato l'inno simbolico della Resistenza partigiana contro fascismo e nazismo. Ti faccio sentire un brano di questo canto nella versione di una cantante, Milva, appassionata cultrice di canti popolari! Milva ha amato, interpretato e valorizzato canti popolari e “impegnati”, portandoli anche nei palcoscenici principali e incidendoli nei suoi album.  Quella che nasce dalla fatica e dalla durezza del lavoro delle mondine, e che negli anni è stata poi trasformata in un canto di lotta politica e simbolo di libertà. Oggi, è diventata un inno cantato in tutto il mondo, oltre che per questioni politiche e sociali anche grazie alla serie “La casa de Papel”. In questo episodio del podcast ti faccio ascoltare brani che sono già nella tua memoria sonora e ti aiuto a creare una categoria identificativa della modalità minore. Sono tutti brani tratti di una selezione sonora intuitiva, immediatamente riconoscibile e internazionale, tutta roba che “suona minore” anche a chi non sa cosa sia una scala.Non sono musicista, non ho intenzione di usare tecnicismi che non padroneggio neppure io. Il mio mantra resta lo stesso: zero tecnicismi, sentire prima di sapere e sfruttare competenze e conoscenze che hai già, in modo da organizzarle.Ascoltiamo Greensleeves. E' una delle melodie più antiche e riconoscibili della tradizione europea. Famosa anche per essere stata affiancata alle melodie natalizie.Intima, narrativa, essenziale. Il minore qui non è drammatico, non è teatrale: è raccolto, ti accompagna dentro una storia, non ti spinge chissà dove nella fantasia. Altro esempio famosissimo, di cui forse non conosci il titolo ma di certo conosci il tema musicale: Sonata al chiaro di luna – primo movimento, di Ludwig van Beethoven. E' probabilmente uno dei brani in minore più conosciuti al mondo. Lento, ipnotico, sospeso. Il minore qui non chiede azione, non chiede energia: chiede ascolto interno, presenza, silenzio. Continuiamo con un esempio pop internazionale: Eleanor Rigby dei Beatles. Il minore, in questo brano racconta un clima sobrio, reale, quotidiano. Enuncia semplicemente le cose come un dato di fatto: è spoglio, umano, diretto, non cerca commozione facile, niente di melodrammatico. Proseguiamo con una sigla che conosciamo da sempre: Heidi Una sigla per bambini, eppure chiaramente in minore. Esprime una atmosfera nostalgica, tenera, intima. Il minore qui racconta di una realtà, non spaventa, non opprime, è quindi accessibile anche all'infanzia. Parla di casa, memoria, legame. Non c'è tristezza o clima “pesante” ma solo calma e fotografia di una realtà.  Ascoltiamo una ninnananna che definirei universale, forse la più cantata. Forse ce l'hai in mente così: suonata con il carillon. E' la ninnananna di Brahms. Originariamente cantata (ti faccio sentire un brano), viene tradott ain altre lingue e cantata ovunque, riconosciuta da chiunque. Il minore qui è avvolgente, rassicurante, non stimola ma calma. Il minore non è tristezza obbligatoria. Così come il maggiore non è “allegria obbligatoria”! È interiorità, è densità emotiva, è uno spazio più raccolto.  Se il maggiore è piena luce in un giorno di sole con il cielo azzurro, il minore è come stare in una stanza con una luce più morbida. Non stai peggio. Respiri diversamente. Se facciamo un'analisi percettiva, possiamo dire che il minore ha alcune caratteristiche molto chiare: lo spazio sonoro si contrae e diventa intimo, privato, quindi l'attenzione si sposta verso l'interno, non genera una spinta immediata all'azione, e porta invece alla presenza. Gli esempi che ho usato appartengono a un repertorio occidentale, non sono universali in senso assoluto. Ma la sensazione che producono, di raccoglimento, presenza, descrizione di una immagine reale, è riconosciuta da moltissimi esseri umani, anche in culture musicali molto diverse. Cambiano i sistemi musicali. Cambiano i nomi. Ma corpo ed emozioni no. Sono Sabina Todaro mi occupo di flamenco e di danze e musiche del mondo arabo dal 1985. Dal 1990 insegno baile flamenco a Milano, a Il Mosaico Danza, e un lavoro sull'espressione delle emozioni che ho chiamato Lyrical Arab Dance. Vediamo come si utilizza il minore nel flamenco. Dato che il flamenco non nasce per rassicurare, ma per raccontare l'esperienza umana per come è, il minore si adatta perfettamente, descrivendo la presenza nell'esperienza. Pochissimi palos vivono stabilmente nel minore molti lo attraversano, lo evocano. I palos che si svolgono su modalità minore: Farruca, Tango de Malaga, lo stile di Fandango de Huelva di Cabezas Rubias, tango de Triana o del Titi, Milonga, Vidalita. La petenera gioca sulla modalità minore, ma non è solo in modalità minore: utilizza un linguaggio tonale instabile in area minore. Vai ad ascoltare i podcast sulla Petenera, se hai la curiosità. Ci sarà un podcast dedicato a chiarire il concetto di tonale e di modale, queste parolacce che fanno impazzire noi che abbiamo la formazione di teoria musicale che si limita alla teoria musicale delle medie con il flauto dolce. Ossia: zero.Molti palos utilizzano in parte il linguaggio minore: Mariana, Granaina, Media granaina, Mirabrás (attraversa maggiore, minore e modalità flamenca), Alegrías de Córdoba, alcuni Fandangos personales, Fandango de Huelva (molte strofe in area minore, con remate in modalità flamenca).  Come sempre, ti invito a sfruttare competenze e conoscenze che hai già, e semplicemente ti aiuto a riunirle sotto un nome, a dar loro una casa 

DATO SOBRE DATO con Daniel Santoro y José Luis Brea 13-02-2026 Entrevistas a: Martín R. Caranta @mrcaranta (Socio del estudio Lisicki, Litvin y Abelovich @lisickilitvin Consultor Tributario) Miguel A. Kiguel @kiguel (Economista)

Miguel A. Kiguel @kiguel (Economista) Dato Sobre Dato @DatosobreDato

Comentario de actualidad del periodista Andreu Manresa

En el capítulo 1.051 de este viernes 13 de febrero, @tomicarrio te cuenta las tres noticias más importantes para que arranques tu día. Además, este viernes una nueva edición de El Cierre de la Semana con Bruno Panighel, economista de Cinq Capital, sobre las perspectivas para las tasas tras la nueva absorción de pesos que hará el Tesoro tras la licitación de esta semana.Seguinos en nuestras redes sociales:Sitio web: ⁠⁠⁠⁠⁠https://bit.ly/4kly4oe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠WhatsApp: ⁠⁠⁠⁠⁠https://bit.ly/49VsQvL⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠https://bit.ly/4aduszZ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Insta: ⁠⁠⁠⁠⁠https://bit.ly/3NUZDsj⁠⁠⁠⁠⁠X: ⁠⁠⁠⁠⁠https://bit.ly/3ZTvXyd⁠⁠⁠⁠⁠Fran Aldaya: ⁠⁠⁠⁠⁠https://bit.ly/4rufwo0⁠

Enrique Quintana, Dir. general editorial de El Financiero

La adicción al juego entre adolescentes sube en España: afecta a más de uno de cada doce chicos de 14 a 18 años. Así lo recoge el informe sobre adicciones comportamentales y otros trastornos adictivos (no ligados al consumo de sustancias) del Plan Nacional Sobre Drogas. Analizamos la cuestión con Consuelo Tomás, psicóloga y responsable del pionero Instituto Valenciano de Ludopatía y Adicciones No Tóxicas y con Miriam Gañán, directora de Azajer, la Asociación Aragonesa de Jugadores de Azar en Rehabilitación.

Podcast de Inversión Inmobiliaria

Bila Manap & Maon start sembang business… terus level Dato & Tan Sri mode activated. Oi geng!

Kickoff di Maracanà con Marco Piccari e Stefano Impallomeni. Ospiti: Mattei:"Sarri ha dato un'anima alla squadra" Impallomeni:"La Lazio si è ritrovata come gruppo" Bonfanti:"Tra Conte e Napoli strade destinate a separarsi" De Carolis:" Il Bologna è impaurito non può scalare la classifica"

Bila Manap & Maon start sembang business… terus level Dato & Tan Sri mode activated. Oi geng!

Wall Street aguarda dato de empleo; la IA sigue asustando a los mercados; EE.UU. emite licencias para que empresas de servicios petroleros operen en Venezuela y hay preocupación por muertes por sarampión en México.Newsletter Cinco cosas: bloom.bg/42Gu4pGLinkedin: https://www.linkedin.com/company/bloomberg-en-espanol/Youtube: https://www.youtube.com/BloombergEspanolWhatsApp: https://whatsapp.com/channel/0029VaFVFoWKAwEg9Fdhml1lTikTok: https://www.tiktok.com/@bloombergenespanolX: https://twitter.com/BBGenEspanolProducción: Laura Millán y Eduardo ThomsonSee omnystudio.com/listener for privacy information.

11/2 Msci Asia Pacific rompe un nuovo record, si allarga il divario con Europa e Wall Street. Nikkei chiuso, rally dello yen su dollaro. Oro e argento risalgono, i nuovi target per il 2026. Bitcoin sotto 69mila dollari. Wall Street futures positivi, oggi dato chiave su inflazione e mercato del lavoro. Corrono i Tresuries, rendimento sotto 4,15% dopo il dato debole su consumi americani. Dollaro ancora in calo. Come cambiano le aspettative per la Fed? Il settore Wealth management è l'ultima vittima delle piattaforme AI, cali per Schwab, Morgan Stanley e Raymond James. Seduta nel segno delle trimestrali, Robinhood delude, Ford maxi perdita per elettrico. Blackstone aumenta partecipazione in Anthropic, continua il deflusso di co-fondatori da XAI. Europa, vigilia di vertice nelle Fiandre: leader dividi. Parlamento Eu voterà accordo commerciale Usa il 24 febbraio, con un caveat. Focus su banche, Mps, Ferrari , Banco Desio, MFE e attesa per i numeri di Essilor Luxottica.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Escuche esta y más noticias de LA PATRIA Radio de lunes a viernes por los 1540 AM de Radio Cóndor en Manizales y en www.lapatria.com, encuentre videos de las transmisiones en nuestro Facebook Live: www.facebook.com/lapatria.manizales/videos

El manual de inspiración etnográfica: método y descripción —de Enriqueta Lerma Rodríguez y Gustavo Peñalosa Castro— no se presenta como un compendio rígido de pasos técnicos, sino como una provocación epistemológica a repensar la etnografía desde sus entrañas más sensibles. Publicado por el Centro de Investigaciones Multidisciplinarias sobre Chiapas y la Frontera Sur de la UNAM en 2025, el libro despliega una apuesta formativa: identificar con imaginación cómo el método etnográfico puede problematizar la realidad social en lugar de domesticarla

Federico y Luis F. Quintero comentan el informe de la ECIU.

Keluar Sekejap bersiaran secara langsung dari Coastal Combat, Desaru Coast, membincangkan bagaimana sukan kini menjadi antara pemacu utama pelancongan serta penjenamaan Johor di peringkat antarabangsa, khususnya di Desaru Coast.Segmen pertama menampilkan Dato' Muhammad Shahnaz Azmi, Presiden Muay Thai Malaysia, yang berkongsi perkembangan sukan Muay Thai di Malaysia, penyertaan atlet antarabangsa dalam Coastal Combat, serta peranan acara seumpama ini dalam menyokong agenda Visit Johor 2026 dan memposisikan Desaru Coast sebagai destinasi sukan bertaraf dunia.Segmen kedua bersama Murray Aitken, Pengurus Besar Hard Rock Hotel Desaru Coast, mengupas peranan jenama antarabangsa dalam menyokong penganjuran acara sukan bertaraf dunia seperti IRONMAN dan World Amateur Golfers Championship (WAGC). Perbincangan turut menyentuh kekuatan infrastruktur, fasiliti, serta kebolehcapaian Desaru Coast sebagai lokasi strategik bagi acara sukan dan MICE.Antara acara utama yang bakal berlangsung ialah IRONMAN 70.3 Desaru Coast, 5150 Desaru Coast, Sprint Triathlon, dan IRONKIDS Desaru Coast pada 10–12 Julai 2026, serta World Amateur Golfers Championship (WAGC) pada 23–31 Oktober 2026.Ikuti perkembangan terkini di:

Natalia Hernández reflexiona en La Brújula sobre la influencia que deja este largometraje de Netflix que ha batido muchos récords en la plataforma y en el cine de animación.

Estas redes sociales funcionan con un modelo de negocio que consiste en ganar dinero a paladas a base de jugar con la salud mental de millones de personas y la calidad de la democracia de cientos de países. Jaime García Cantero y Nuño Domínguez analizan el anuncio de Pedro Sánchez sobre la prohibición de las redes sociales a menores y reprochan al gobierno que siga anunciando todo en esas mismas redes sociales. Que dejen de regarlas con dinero público contratando grandes campañas de publicidad institucional tal vez sea más eficaz que abandonarse a la tentación de responder a los oligarcas con frases ingeniosas en esas mismas redes que quieres cerrar a menores. Además del mal ejemplo que se da así a los chavales. Se hacen anuncios solemnes, pero también se trivializan las redes. Que no son "la calle" ni "una plaza pública": son un centro comercial privado. Sería importante, como está intentando hacer Francia con X, entrar en el algoritmo y modificarlo para que no sea tan dañino y tan adictivo. Porque el problema no tiene por qué ser la existencia de redes sociales en general, sino el funcionamiento de estas redes (que pertenecen a estos señores) en particular. Dato interesante: solo han clamado contra la medida X y Telegram, que no hacen dinero. Las que sí hacen dinero (META, Google), han recibido el anuncio de Sánchez con un clamoroso silencio.Además hablamos del retraso de la misión a la luna, de la fusión de Space X y X AI, de los nuevos despidos en el Washington Post, que deja ese estandarte de la información en la miseria, y de los avances contra el Párkinson. 

Escuche esta y más noticias de LA PATRIA Radio de lunes a viernes por los 1540 AM de Radio Cóndor en Manizales y en www.lapatria.com, encuentre videos de las transmisiones en nuestro Facebook Live: www.facebook.com/lapatria.manizales/videos

Episod 186 Audio Siar Keluar Sekejap membincangkan Rancangan Pendidikan Malaysia 2026–2035 yang diumumkan oleh Perdana Menteri, Dato' Seri Anwar Ibrahim, pada minggu lalu. Antara keputusan utama yang disentuh ialah cadangan kemasukan Darjah 1 pada usia enam tahun serta pelaksanaan Matriks Pembelajaran bagi murid Darjah 4 dan pelajar Tingkatan 3.Episod ini turut mengupas kes rasuah Angkatan Tentera Malaysia (ATM) yang mencatat sejarah apabila, buat pertama kalinya, bekas Panglima Angkatan Tentera Malaysia dan bekas Panglima Tentera Darat ditahan serta didakwa atas pertuduhan rasuah dan salah guna kuasa.Selain itu, perbincangan turut menyentuh Tahun Melawat Malaysia, yang menyaksikan Malaysia mengatasi Thailand dari segi jumlah pelawat. Namun, episod ini menekankan cabaran berterusan berkaitan perbelanjaan pelancong yang masih rendah di dalam negara.Bagi isu antarabangsa, Keluar Sekejap mengulas rancangan bekas Presiden Amerika Syarikat, Donald Trump, untuk mengadakan perbincangan segera berhubung usaha mengambil alih Greenland, serta cadangan penubuhan Board of Peace.Kami juga telah melancarkan Kelas Sekejap! Kelas Sekejap ialah Aplikasi Bahasa Inggeris Pertama di Malaysia Untuk Belajar Dengan Bertutur. Dikuasakan oleh AI - Pelajaran disesuaikan ikut minat, matlamat dan tahap anda. Muat turun di Apple Store dan Play Store sekarang!Ikuti Kelas Sekejap untuk pelancaran eksklusif hari ini!Instagram: https://www.instagram.com/kelas_sekejap TikTok: https://www.tiktok.com/@kelas_sekejap

En este episodio de Trade Talks (con Jnesto ausente por enfermedad tras llegar a España), el equipo repasa el cierre de año con enfoque en el “Santa Rally”, destacando la recuperación de las tecnológicas y movimientos recientes en Nvidia, Broadcom (AVGO), Amazon y Google, impulsados por un dato de inflación más frío de lo esperado y un crecimiento del PIB por encima de la expectativa, con fuerte peso de la inversión en AI y data centers. También conversan sobre cómo la eficiencia corporativa (AI + recortes) está elevando márgenes, debaten el potencial de Meta en 2026 y el impacto de los Meta Glasses como pieza clave de hardware y distribución de contenido. Además, analizan el rol de Oracle en el acuerdo de TikTok y el valor estratégico de la data y el cloud, tocan el tema espacial (Space Force, Artemis y el posible IPO de SpaceX) y cierran con lectura de sentimiento de mercado: VIX en mínimos/avaricia extrema, puts baratos como cobertura, y sus top picks para el 2026 (Amazon y Meta).#DalePlay y #LearnWhileInvesting

Natalia Hernández reflexiona en La Brújula sobre la influencia de ese año una década después en las redes sociales.

Podcast de Inversión Inmobiliaria

Esta noche en EL CONSULTORIO BURSÁTIL analizamos el impacto del último dato de inflación en EE.UU. y cómo lo está leyendo realmente el mercado. ¿Ha dejado de importar la inflación? ¿Está empezando una nueva narrativa en Wall Street? Oferta de Año Nuevo - del 23 de diciembre al 28 de enero de 2026 Porque los regalos no acaban en Navidad... 50% en 1 año de Pro y Pro+ 55% en 2 años de Pro y Pro+ Y lo mejor: podrás seguir disfrutando de un 15% adicional cuando uses el código lws + link. Eso significa que podrás conseguir hasta un 70% de descuento en InvestingPro durante estos días. https://www.investing-referral.com/lws Código: lws Índice: 00:00 -- Inicio 08:30 – Euforia de mercado: gestión de riesgo y toma de beneficios 11:40 – AST SpaceMobile: venta parcial, volatilidad y próximos catalizadores 12:35 – Kosmos Energy: subida fuerte y riesgo petróleo 14:15 – Evolution AB: caída de múltiplos y tesis value 17:20 – Pluxee: resultados, Brasil y paciencia del mercado 20:45 – Constellation Software y la disrupción por IA 25:10 – Nuclear y riesgo binario: ASP Isotopes 28:10 – Mejores ideas del año: Basic-Fit, Golar LNG, Glencore 31:55 – PayPal: crecimiento vs disrupción 36:35 – Estaño y dividendos: Alphamin Resources 39:35 – Carbón y offshore: Warrior Met Coal y Valaris 54:35 – Cobre a 6$: ¿queda recorrido o toca prudencia? Dos cosas que debes saber: 1 - Cada día mandamos un email con una idea, estrategia o reflexión privada para que avances más rápido en tu camino como inversor. El de hoy ya te lo has perdido, si quieres recibir el de mañana, te apuntas en: https://locosdewallstreet.com/7-errores/ 2 - Al apuntarte recibes un video titulado «7 errores fatales (muy habituales) en la selección de oportunidades en bolsa». Me da igual en lo que inviertas, tus años de experiencia o el tamaño de tu cartera. Si inviertes deberías verlo (antes de tomar una decisión de la que poder arrepentirte). Lo recibes al apuntarte en nuestra newsletter aquí: https://locosdewallstreet.com/7-errores/ ══════════════ DISCLAIMER El contenido de este canal de YouTube tiene exclusivamente fines educativos y no constituye asesoramiento financiero ni recomendaciones de inversión. Todos los temas tratados están diseñados para ayudar a los espectadores a entender mejor el mundo de las finanzas, pero las decisiones de inversión deben tomarse de forma personal y bajo la responsabilidad de cada individuo. Invertir en mercados financieros conlleva riesgos significativos debido a su complejidad y volatilidad. Es posible perder parte o la totalidad del capital invertido. Por ello, es fundamental que realices tu propio análisis antes de tomar cualquier decisión y, si lo consideras necesario, consultes con un profesional financiero acreditado. Recomendamos: - Contar con un fondo de emergencia equivalente a al menos tres meses de tus gastos básicos antes de invertir. - Analizar muy detenidamente y con precisión cualquier inversión. - En caso de duda consultes con un asesor financiero certificado por CNMV - Mantenerte alejado de promesas de rentabilidades astronómicas, dinero rápido u otros esquemas engañosos. En Locos de Wall Street, nuestra misión es fomentar una educación financiera sólida, ética y accesible para todos, ayudando a nuestros seguidores a tomar decisiones informadas y responsables. ══════════════ #finanzas #inversiones #inflacion #WallStreet #consultoriobursatil #LWS #locosdewallstreet

En este segmento de Grupo Sociedad de Tasación, Enrique Vinagrero analiza el costo de construcción de obra nueva en España, destacando un aumento del 3,27% interanual. A pesar de la inflación controlada, los costos siguen subiendo debido a la falta de mano de obra cualificada y nuevas regulaciones. Sin embargo, el sector muestra avances en eficiencia energética, reduciendo el consumo de energía y las emisiones de CO2. Se discute la resiliencia del sector inmobiliario y la importancia de equilibrar costos con mejoras tecnológicas. Descubre más sobre el semáforo inmobiliario y los índices de confianza de Sociedad de Tasación.

Tertulia previa al 33 Congreso Aslan en la que han intervenido: Isidre Royo, Senior Product Manager de Business Observability de Dynatrace; Andrés Miramontes, Regional Sales Manager Iberia de Quantum; Andrés Marín, Country Manager de MongoDB y Luis Miguel Domínguez, VP de Área Iberia de ServiceNow.

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

Podcast de Inversión Inmobiliaria

En entrevista con MVS Noticias, Luis Miguel González, director editorial de El Economista, explicó las implicaciones reales que este dato tiene en contratos, expectativas económicas y proyecciones para este 2026.See omnystudio.com/listener for privacy information.